Asia
The U.S. Government is increasing the measures it is taking to counter what it sees as a growing threat to scientific intellectual property from China.
Moving into the holidays and the fast-approaching end of the year, the U.S. Food and Drug Administration (FDA) got busy wrapping up a number of to-do items. Here’s a look.
This year’s edition saw a rise in overall attendees, with harmonization and innovation driving increased industry dynamism
The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional novel product candidates based on Turnstone’s vaccinia virus platform for future independent development.
The FDA granted Astellas Pharma and Seattle Genetics accelerated approval for Padcev, a first-of-its-kind treatment for adult patients with metastatic urothelial bladder cancer.
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
Consumer healthcare company HRA Pharma will be expanding internationally into the Middle East, with the UAE and Kuwait being the first movers with the iconic footcare care brand Compeed®.
Almost one month after BeiGene’s Bruton’s kinase inhibitor Brukinsa won accelerated approval for mantle cell lymphoma, the company reported the drug failed to hit the mark in a late-stage trial assessing the drug as a treatment for Waldenström’s macroglobulinemia.
With the latest approval, Xtandi, an androgen receptor inhibitor, is now the only oral treatment approved by the FDA for three distinct types of advanced prostate cancer – non-metastatic and metastatic castration-resistant prostate cancer (CRPC) and mCSPC.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
PRESS RELEASES